Insufficient Evidence of Cimetidine Benefit in Protoporphyria-Reply.

JAMA Dermatol

Department of Dermatology, Stanford University, Palo Alto, California2College of Physicians and Surgeons, Columbia University, New York, New York.

Published: February 2017

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2016.4050DOI Listing

Publication Analysis

Top Keywords

insufficient evidence
4
evidence cimetidine
4
cimetidine benefit
4
benefit protoporphyria-reply
4
insufficient
1
cimetidine
1
benefit
1
protoporphyria-reply
1

Similar Publications

Objectives: Explore humanitarian healthcare professionals' (HCPs) perceptions about implementing children's palliative care and to identify their educational needs and challenges, including learning topics, training methods, and barriers to education.

Methods: Humanitarian HCPs were interviewed about perspectives on children's palliative care and preferences and needs for training. Interviews were transcribed, coded, and arranged into overarching themes.

View Article and Find Full Text PDF

The gut barrier encompasses several interactive, physical, and functional components, such as the gut microbiota, the mucus layer, the epithelial layer and the gut mucosal immunity. All these contribute to homeostasis in a well-regulated manner. Nevertheless, this frail balance might be disrupted for instance by westernized dietary habits, infections, pollution or exposure to antibiotics, thus diminishing protective immunity and leading to the onset of chronic diseases.

View Article and Find Full Text PDF

Background: Polyfluoroalkyl chemicals (PFCs) present potential health risks due to their persistence and bioaccumulation. However, there is currently insufficient evidence regarding their impact on cardiovascular disease (CVD). Consequently, it is imperative to investigate the correlation between PFCs and CVD.

View Article and Find Full Text PDF

Lipid-Lowering Drugs and Pulmonary Vascular Disease: A Mendelian Randomization Study.

Pulm Circ

January 2025

Center of Gerontology and Geriatrics National Clinical Research Center for Geriatrics,West China Hospital, Sichuan University Chengdu China.

The therapeutic value of lipid-lowering drugs in pulmonary vascular disease remains uncertain due to insufficient studies and evidence. This study aims to investigate the causal effects of lipid-lowering drugs (specifically, inhibitors of APOB, CETP, HMGCR, NPC1L1, and PCSK9) on pulmonary vascular diseases using a Mendelian randomization (MR) approach. We utilized summary-level statistics from genome-wide association studies (GWAS) to simulate the exposure to low-density lipoprotein cholesterol (LDL-C) and its outcomes on pulmonary arterial hypertension (PAH), pulmonary embolism (PE), and pulmonary heart disease (PHD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!